Florida-based inhaled drug developer Transpire Bio has announced the initiation of a Phase 1 trial of a synthetic inhaled cannabidiol formulation, which the company is developing for Parkinson’s disease psychosis and for other central nervous system conditions. Transpire is also developing inhaled CBD for the treatment of glioblastoma and its TRB-ONC1 formulation recently received orphan drug designation from the FDA for that indication.
The company’s pipeline also includes TRB-ILD1, an inhaled phosphodiesterase-4 (PDE4) inhibitor for the treatment of idiopathic pulmonary fibrosis, which also recently received orphan designation, and two other programs for IPF. In June 2025, Transpire announced that it had acquired a license to develop Suzhou Intragrand Pharma’s ITG-1052 PDE4 inhibitor.
Transpire notes that is also developing an inhaled therapy for the treatment of asthma and COPD and announced the initiation of a Phase 1 study of that product in October 2024. In September 2025, the company announced that the FDA had accepted its ANDA for a generic of Breo Ellipta fluticasone furoate / vilanterol DPI. The company says that it also has an inhaled GLP-1 formulation and a product for the treatment of pulmonary arterial hypertension (PAH) in development.
Transpire Bio Chief Medical Officer Mark Lepore commented, “There is a significant unmet medical need for patients suffering from neurodegenerative disorders. Patients seek therapies that not only improve symptoms and quality of life, but also those that can do so while minimizing adverse effects. Using the inhalation route of administration to treat CNS disorders has not been widely leveraged, and we at Transpire Bio are looking forward to advancing our science and technologies to get these innovative therapies into the hands of patients.”
CEO Xian-Ming Zeng said, “The dosing of the first human subject using our novel formulation technology platform is yet another significant milestone for our company as we continue to advance our pipeline of innovative, inhaled medicines.”
Read the Transpire Bio press release
